Latest market price
46.59
+2.30+5.19%
CNMDQT64CONMED Corporation·NYSE
46.59+5.19%
TA
Loading chart...
Signal & projected range
QT Score upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E19.25EPS (ttm)2.42Insider Own2.89%Shs Outstand29.80MPerf Week-2.29%
Market Cap1.39BForward P/E9.81EPS next Y4.75Insider Trans0.00%Shs Float29.69MPerf Month0.58%
Enterprise Value2.16BPEG1.92EPS next Q1.27Short Float6.44%Perf Quarter-7.56%
Income74.00MP/S1.01EPS this Y1.61%Short Ratio4.62Perf Half Y29.85%
Sales1.37BP/B1.31EPS next Y3.84%ROA3.19%Short Interest1.91MPerf YTD14.75%
Book/sh35.57P/C28.93EPS next 5Y10.05%ROE7.07%52W High53.66 -13.18%Perf Year4.72%
Cash/sh1.61P/FCF10.44EPS past 3/5Y— 36.38%ROIC5.73%52W Low31.44 48.19%Perf 3Y-50.64%
Dividend Est.—EV/EBITDA10.27Sales past 3/5Y9.55% 9.77%Gross Margin57.20%Volatility5.49% 4.30%Perf 5Y-67.66%
Dividend TTM—EV/Sales1.58EPS Y/Y TTM17.93%Oper. Margin12.11%ATR (14)2.01Perf 10Y18.25%
Dividend Ex-DateSep 15, 2025Quick Ratio0.70Sales Y/Y TTM1.63%Profit Margin5.36%RSI (14)50.35Recom2.71
Dividend Gr. 3/5Y-9.14% -5.59%Current Ratio1.49EPS Q/Q-3.70%SMA200.78%Beta0.89Target Price37.50
Payout8.43%Debt/Eq0.77Sales Q/Q-0.88%SMA50-0.84%Rel Volume1.21Prev Close44.29
Employees3,900LT Debt/Eq0.60EarningsJan 27SMA20012.46%Avg Volume366.37KPrice46.59
IPO DateJul 23, 1987Option/ShortYes / YesEPS/Sales Surpr.3.70% -0.22%Net Debt/EBITDA3.66Volume444,129Change5.19%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-13-26ReiteratedWells FargoEqual Weight$39
Jul-08-26InitiatedBMO CapitalMarket Perform$36
Jun-29-26DowngradeB of A SecuritiesNeutral → Underperform
Mar-17-26DowngradePiper SandlerOverweight → Neutral
Jun-12-25DowngradeNeedhamBuy → Hold
May-01-25ReiteratedNeedhamBuy$97 → $61
Apr-28-25DowngradeStifelBuy → Hold
Feb-06-25DowngradeJP MorganOverweight → Neutral
Oct-04-24ReiteratedNeedhamBuy$107 → $97
Apr-25-24ReiteratedNeedhamBuy$107
Latest News· Times ET
Nov-02-26
Oct-29-26
Oct-29-2603:06AM
Oct-28-26
Oct-16-26
Oct-06-26
Oct-02-26
Oct-01-26
Sep-24-26
Sep-24-2606:40AM
Sep-18-26
Sep-16-26
Sep-08-26
Company

CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,3691,3741,3071,245—————
Cost of Goods Sold Incl. D&A586649574568—————
Gross Profit782725733676—————
Selling, General and Administrative Excl. Other556528478503—————
Research and Development63565453—————
Other Operating Expense-2010—————
Operating Income165141200121—————
Interest Expense33313740—————
Unusual Expense
—————————
Non-Operating Income (Expense)-27-3900—————
Net Income Before Taxes1047116381—————
Income Taxes32243116—————
Consolidated Net Income744713264—————
Net Income From Continuing Operations744713264—————
Net Income744713264—————
EPS (Recurring)2.421.524.292.10—————
EPS (Basic, Before Extraordinaries)2.421.524.292.10—————
EPS (Diluted)2.421.514.262.04—————
EBITDA210176252172—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio19.2526.8916.0753.68—————
Price To Sales Ratio1.020.921.622.73—————
Gross Margin57.1252.7756.0854.30—————
Operating Margin12.0510.2615.309.72—————
Net Margin5.413.4210.105.14—————
Shares Outstanding30313131—————
Market Capitalization1,3981,2592,1223,395—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$58.40$50.97$43.54$36.11$28.68● Close Price0.00K40.27K80.55K120.82K161.09KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kelderman KimDirectorSep 08 '26Option Exercise0.005000500Sep 10
Lalomia BrentExecutive VP RA, QAMar 06 '26Option Exercise0.00750941Mar 10
Kaye MarkDirectorFeb 24 '26Option Exercise0.001520152Feb 26
Glaze RichardChief Information OfficerNov 21 '25Sale41.2125710,5910Nov 24
Glaze RichardChief Information OfficerNov 20 '25Option Exercise0.003750375Nov 21
Garner Todd WExecutive Vice President & CFONov 06 '25Sale43.003,500150,5001,836Nov 07
Foust Hollie KGeneral Counsel & Corp SecNov 04 '25Option Exercise0.004,00004,000Nov 05
Garner Todd WExecutive Vice President & CFOOct 31 '25Option Exercise0.007,50007,500Nov 03
Farkas CharlesDirectorSep 12 '25Sale53.522,000107,04914,859Sep 15
Garner Todd WExecutive Vice President & CFOAug 07 '25Sale52.4559831,3650Aug 08
Bronson David M.DirectorJun 03 '25Option Exercise0.00479017,241Jun 04
Farkas CharlesDirectorJun 03 '25Option Exercise0.00479016,859Jun 04
Aronson Martha GoldbergDirectorJun 03 '25Option Exercise0.00479012,391Jun 04
Concannon BrianDirectorJun 03 '25Option Exercise0.00479010,116Jun 04
Council LaVerne HDirectorJun 03 '25Option Exercise0.0047904,048Jun 04
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.